Involvement of deleted chromosome 5 in complex chromosomal aberrations in newly diagnosed myelodysplastic syndromes (MDS) is correlated with extremely adverse prognosis

Leukemia Research

Volumn 38, Issue 5, 2014, Pages 537-544

  Zemanova, Zuzana ^a   Michalova, Kyra ^a,b   Buryova, Halka ^a   Brezinova, Jana ^b   Kostylkova, Karla ^a   Bystricka, Dagmar ^a   Novakova, Milena ^a   Sarova, Iveta ^b   Izakova, Silvia ^a   Lizcova, Libuse ^a   Ransdorfova, Sarka ^b   Krejcik, Zdenek ^b   Merkerova, Michaela Dostalova ^b   Dohnalova, Alena ^a   Siskova, Magda ^a   Jonasova, Anna ^a   Neuwirtova, Radana ^a   Cermak, Jaroslav ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

Author keywords

Chromothripsis; Complex chromosomal aberrations; Deletion 5q; Genome instability; Myelodysplastic syndromes

Indexed keywords

ADULT; AGED; ARTICLE; CHROMOSOME ABERRATION; CHROMOSOME DELETION 5; CHROMOSOME NUMBER; CHROMOSOME REARRANGEMENT; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; GENOME ANALYSIS; HUMAN; HUMAN CELL; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MONOSOMY; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; TRISOMY;

CHROMOTHRIPSIS; COMPLEX CHROMOSOMAL ABERRATIONS; DELETION 5Q; GENOME INSTABILITY; MYELODYSPLASTIC SYNDROMES;

ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 5; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; HUMANS; KARYOTYPE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 84898857814     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.01.012     Document Type: Article

References (37)

1. Haase D. Cytogenetic features in myelodysplastic syndromes. Ann Hematol 2008, 87:512-526.
2. Haase D., Germing U., Schanz J., Pfeilstöcker M., Nösslinger T., Hildebrandt B., et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007, 110(13):4385-4395.
3. Brezinova J., Zemanova Z., Bystricka D., Sarova I., Lizcova L., Malinova E., et al. Deletion of the long arm but not the 5q31 region of chromosome 5 in myeloid malignancies. Leuk Res 2012, 36(3):e43-e45.
4. Boultwood J., Pellagatti A., McKenzie A.N., Wainscoat J.S. Advances in the 5q syndrome. Blood 2010, 116(26):5803-5811.
5. Ebert B.L. Molecular dissection of the 5q deletion in myelodysplastic syndrome. Semin Oncol 2011, 38(5):621-626.
6. Jerez A., Gondek L.P., Jankowska A.M., Makishima H., Przychodzen B., Tiu R.V., et al. Clinical, and genomic correlates of 5q myeloid malignancies revisited. J Clin Oncol 2012, 30(12):1343-1349.
7. Boultwood J., Fidler C., Strickson A.J., Watkins F., Gama S., Kearney L., et al. Narrowing and genomic annotation of the commonly deleted region on the 5q- syndrome. Blood 2002, 99:4638-4641.
8. Eisenmann K.M., Dykema K.J., Matheson S.F., Kent N.F., DeWard A.D., West R.A., et al. 5q- myelodysplastic syndromes: chromosome 5q genes direct a tumor-suppression network sensing actin dynamics. Oncogene 2009, 28(39):3429-3441.
9. Ebert B.L., Pretz J., Bosco J., Chang C.Y., Tamayo P., Galili N., et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference free. Nature 2008, 451:335-339.
10. Brunning R.D., Orazi A., Germing U., Le Beau M.M., Porwit A., Baumann I., et al. Myelodysplastic syndromes/neoplasms, overview. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, IARC Press, Lyon, France. S.H. Swerdlow, E. Campo, N.L. Harris (Eds.).
11. Morel P., Hebbar M., Lai J.L., Duhamel A., Preudhomme C., Wattel E., et al. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia 1993, 7(9):1315-1323.
12. Nevill T.J., Fung H.C., Shepherd J.D., Horsman D.E., Nantel S.H., Klingemann H.G., et al. Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood 1998, 92(6):1910-1917.
13. Greenberg P.L., Tuechler H., Schanz J., Sanz G., Garcia-Manero G., Solé F., et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012, 120(12):2454-2465.
14. Stephens P.J., Greenman C.D., Fu B., Yang F., Bignell G.R., Mudie L.J., et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 2011, 144(1):27-40.
15. ISCN An International System for Human Cytogenetic Nomenclature 2013, S. Karger, Basel. L.G. Shaffer, J. McGowan-Jordan, M. Schmid (Eds.).
16. Kaplan E., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
17. Peto R., Pike M.C., Armitage P., Breslow N.E., Cox N.R., Howard S.V., et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Cancer 1977, 35:1-39.
18. Evers C., Beier M., Poelitz A., Hildebrandt B., Servan K., Drechsler M., et al. Molecular definition of chromosome arm 5q deletion end points and detection of hidden aberrations in patients with myelodysplastic syndromes and isolated del(5q) using oligonucleotide array CGH. Genes Chromosomes Cancer 2007, 46(12):1119-1128.
19. Mallo M., Del Rey M., Ibáñez M., Calasanz M.J., Arenillas L., Larráyoz M.J., et al. Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations. Br J Haematol 2013, 162(1):74-86.
20. Kakazu N., Taniwaki M., Horiike S., Nishida K., Tatekawa T., Nagai M., et al. Combined spectral karyotyping and DAPI banding analysis of chromosome abnormalities in myelodysplastic syndrome. Genes Chromosomes Cancer 1999, 26(4):336-345.
21. Mrózek K., Heinonen K., Theil K.S., Bloomfield C.D. Spectral karyotyping in patients with acute myeloid leukemia and a complex karyotype shows hidden aberrations, including recurrent overrepresentation of 21q, 11q, and 22q. Genes Chromosomes Cancer 2002, 34(2):137-153.
22. Trost D., Hildebrandt B., Beier M., Müller N., Germing U., Royer-Pokora B. Molecular cytogenetic profiling of complex karyotypes in primary myelodysplastic syndromes and acute myeloid leukemia. Cancer Genet Cytogenet 2006, 165:51-63.
23. Herry A., Douet-Guilbert N., Morel F., Le Bris M.J., De Braekeleer M. Redefining monosomy 5 by molecular cytogenetics in 23 patients with MDS/AML. Eur J Haematol 2007, 78:457-467.
24. Mrózek K. Cytogenetic, molecular genetics, and clinical characteristics of acute myeloid leukemia with a complex karyotype. Semin Oncol 2008, 35(4):365-377.
25. Galván A.B., Mallo M., Arenillas L., Salido M., Espinet B., Pedro C., et al. Does monosomy 5 really exist in myelodysplastic syndromes and acute myeloid leukemia. Leuk Res 2010, 34:1242-1245.
26. Solé F., Luño E., Sanzo C., Espinet B., Sanz G.F., Cervera J., et al. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. Haematologica 2005, 90:1168-1178.
27. Schanz J., Tüchler H., Solé F., Mallo M., Luño E., Cervera J., et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 2012, 30(8):820-829.
28. Schoch C., Haferlach T., Bursch S., Gerstner D., Schnittger S., Dugas M., et al. Loss of genetic material is more common than gain in acute myeloid leukemia with complex aberrant karyotype: a detailed analysis of 125 cases using conventional chromosome analysis and fluorescence in situ hybridization including 24-color FISH. Genes Chromosomes Cancer 2002, 35(1):20-29.
29. Alvarez S., Cigudosa C. Gains, loss and complex karyotypes in myeloid disorders: a light at the end of the tunnel. Hematol Oncol 2005, 23:18-25.
30. Cordoba I., González-Porras J.R., Nomdedeu B., Luño E., de Paz R., Such E., et al. Better prognosis for patients with del(7q) than for patients with monosomy 7 in myelodysplastic syndrome. Cancer 2012, 118(1):127-133.
31. Lizcova L., Zemanova Z., Malinova E., Jarosova M., Mejstrikova E., Smisek P., et al. A novel recurrent chromosomal aberration involving chromosome 7 in childhood MDS. Cancer Genet Cytogenet 2010, 201:52-56.
32. Haferlach C., Alpermann T., Schnittger S., Kern W., Chromik J., Schmid Ch Pielken H.J., et al. Prognostic value of monosomal karyotype in acute myeloid leukemia: a study on 824 cases with aberrant karyotype. Blood 2012, 119:2122-2125.
33. Breems D.A., Van Putten W.L., De Greef G.E., Van Zelderen-Bhola S.L., Gerssen-Schoorl K.B., Mellink C.H., et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol 2008, 26:4791-4797.
34. Valcárcel D., Ademà V., Solé F., Ortega M., Nomdedeu B., Sanz G., et al. Complex, not monosomal, karyotype is the cytogenetic marker of poorest prognosis in patients with primary myelodysplastic syndrome. J Clin Oncol 2013, 31(7):916-922.
35. Schanz J., Tüchler H., Solé F., Mallo M., Luño E., Cervera J., et al. Monosomal karyotype in MDS: explaining the poor prognosis?. Leukemia 2013, 27(10):1988-1995.
36. Vajen B., Thomay K., Schlegelberger B. Induction of chromosomal instability via telomere dysfunction and epigenetic alterations in myeloid neoplasia. Cancers 2013, 5:857-874.
37. Maher C.A., Wilson R.K. Chromothripsis and human disease: piecing together the shattering process. Cell 2012, 148(0):29-32.